Update on the Management of Pediatric Psoriasis: An Italian Consensus

Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Peris, Ketty [verfasserIn] Fortina, Anna Belloni Bianchi, Luca Fabbrocini, Gabriella Gisondi, Paolo Balato, Anna Bardazzi, Federico Bernardini, Nicoletta Bonamonte, Domenico Bongiorno, Maria Rita Buligan, Cinzia Cusano, Francesco Del Giudice, Maria Beatrice De Felici El Hachem, May Fargnoli, Maria Concetta Gualdi, Giulio Guarneri, Claudio Hansel, Katharina Malara, Giovanna Mazzatenta, Carlo Micali, Giuseppe Narcisi, Alessandra Neri, Iria Oranges, Teresa Panzone, Michele Parodi, Aurora Restano, Lucia Simonetti, Oriana Venturini, Marina Di Lernia, Vito

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Schlagwörter:	Adolescents Biologics Children Corticosteroid-sparing Health-related quality of life Pediatric psoriasis Plaque psoriasis Systemic therapy Topical corticosteroids

Anmerkung:	© The Author(s) 2022. corrected publication 2022

Übergeordnetes Werk:	Enthalten in: Dermatology and therapy - Heidelberg : Springer, 2011, 12(2022), 8 vom: 01. Juli, Seite 1753-1775
Übergeordnetes Werk:	volume:12 ; year:2022 ; number:8 ; day:01 ; month:07 ; pages:1753-1775

Links:	Volltext

DOI / URN:	10.1007/s13555-022-00758-2

Katalog-ID:	SPR047789522

Internformat


LEADER	01000caa a22002652 4500
001	SPR047789522
003	DE-627
005	20230519155740.0
007	cr uuu---uuuuu
008	220808s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s13555-022-00758-2 \|2 doi
035			\|a (DE-627)SPR047789522
035			\|a (SPR)s13555-022-00758-2-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Peris, Ketty \|e verfasserin \|4 aut
245	1	0	\|a Update on the Management of Pediatric Psoriasis: An Italian Consensus
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s) 2022. corrected publication 2022
520			\|a Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis.
650		4	\|a Adolescents \|7 (dpeaa)DE-He213
650		4	\|a Biologics \|7 (dpeaa)DE-He213
650		4	\|a Children \|7 (dpeaa)DE-He213
650		4	\|a Corticosteroid-sparing \|7 (dpeaa)DE-He213
650		4	\|a Health-related quality of life \|7 (dpeaa)DE-He213
650		4	\|a Pediatric psoriasis \|7 (dpeaa)DE-He213
650		4	\|a Plaque psoriasis \|7 (dpeaa)DE-He213
650		4	\|a Systemic therapy \|7 (dpeaa)DE-He213
650		4	\|a Topical corticosteroids \|7 (dpeaa)DE-He213
700	1		\|a Fortina, Anna Belloni \|4 aut
700	1		\|a Bianchi, Luca \|4 aut
700	1		\|a Fabbrocini, Gabriella \|4 aut
700	1		\|a Gisondi, Paolo \|4 aut
700	1		\|a Balato, Anna \|4 aut
700	1		\|a Bardazzi, Federico \|4 aut
700	1		\|a Bernardini, Nicoletta \|4 aut
700	1		\|a Bonamonte, Domenico \|4 aut
700	1		\|a Bongiorno, Maria Rita \|4 aut
700	1		\|a Buligan, Cinzia \|4 aut
700	1		\|a Cusano, Francesco \|4 aut
700	1		\|a Del Giudice, Maria Beatrice De Felici \|4 aut
700	1		\|a El Hachem, May \|4 aut
700	1		\|a Fargnoli, Maria Concetta \|4 aut
700	1		\|a Gualdi, Giulio \|4 aut
700	1		\|a Guarneri, Claudio \|4 aut
700	1		\|a Hansel, Katharina \|4 aut
700	1		\|a Malara, Giovanna \|4 aut
700	1		\|a Mazzatenta, Carlo \|4 aut
700	1		\|a Micali, Giuseppe \|4 aut
700	1		\|a Narcisi, Alessandra \|4 aut
700	1		\|a Neri, Iria \|4 aut
700	1		\|a Oranges, Teresa \|4 aut
700	1		\|a Panzone, Michele \|4 aut
700	1		\|a Parodi, Aurora \|4 aut
700	1		\|a Restano, Lucia \|4 aut
700	1		\|a Simonetti, Oriana \|4 aut
700	1		\|a Venturini, Marina \|4 aut
700	1		\|a Di Lernia, Vito \|0 (orcid)0000-0002-8961-7108 \|4 aut
773	0	8	\|i Enthalten in \|t Dermatology and therapy \|d Heidelberg : Springer, 2011 \|g 12(2022), 8 vom: 01. Juli, Seite 1753-1775 \|w (DE-627)723900000 \|w (DE-600)2680284-3 \|x 2190-9172 \|7 nnns
773	1	8	\|g volume:12 \|g year:2022 \|g number:8 \|g day:01 \|g month:07 \|g pages:1753-1775
856	4	0	\|u https://dx.doi.org/10.1007/s13555-022-00758-2 \|z kostenfrei \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 12 \|j 2022 \|e 8 \|b 01 \|c 07 \|h 1753-1775

Indexfelder

author_variant	k p kp a b f ab abf l b lb g f gf p g pg a b ab f b fb n b nb d b db m r b mr mrb c b cb f c fc g m b d f d gmbdf gmbdfd h m e hm hme m c f mc mcf g g gg c g cg k h kh g m gm c m cm g m gm a n an i n in t o to m p mp a p ap l r lr o s os m v mv l v d lv lvd
matchkey_str	article:21909172:2022----::paenhmngmnopdarcsraia
hierarchy_sort_str	2022
publishDate	2022
allfields	10.1007/s13555-022-00758-2 doi (DE-627)SPR047789522 (SPR)s13555-022-00758-2-e DE-627 ger DE-627 rakwb eng Peris, Ketty verfasserin aut Update on the Management of Pediatric Psoriasis: An Italian Consensus 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022. corrected publication 2022 Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis. Adolescents (dpeaa)DE-He213 Biologics (dpeaa)DE-He213 Children (dpeaa)DE-He213 Corticosteroid-sparing (dpeaa)DE-He213 Health-related quality of life (dpeaa)DE-He213 Pediatric psoriasis (dpeaa)DE-He213 Plaque psoriasis (dpeaa)DE-He213 Systemic therapy (dpeaa)DE-He213 Topical corticosteroids (dpeaa)DE-He213 Fortina, Anna Belloni aut Bianchi, Luca aut Fabbrocini, Gabriella aut Gisondi, Paolo aut Balato, Anna aut Bardazzi, Federico aut Bernardini, Nicoletta aut Bonamonte, Domenico aut Bongiorno, Maria Rita aut Buligan, Cinzia aut Cusano, Francesco aut Del Giudice, Maria Beatrice De Felici aut El Hachem, May aut Fargnoli, Maria Concetta aut Gualdi, Giulio aut Guarneri, Claudio aut Hansel, Katharina aut Malara, Giovanna aut Mazzatenta, Carlo aut Micali, Giuseppe aut Narcisi, Alessandra aut Neri, Iria aut Oranges, Teresa aut Panzone, Michele aut Parodi, Aurora aut Restano, Lucia aut Simonetti, Oriana aut Venturini, Marina aut Di Lernia, Vito (orcid)0000-0002-8961-7108 aut Enthalten in Dermatology and therapy Heidelberg : Springer, 2011 12(2022), 8 vom: 01. Juli, Seite 1753-1775 (DE-627)723900000 (DE-600)2680284-3 2190-9172 nnns volume:12 year:2022 number:8 day:01 month:07 pages:1753-1775 https://dx.doi.org/10.1007/s13555-022-00758-2 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 8 01 07 1753-1775
spelling	10.1007/s13555-022-00758-2 doi (DE-627)SPR047789522 (SPR)s13555-022-00758-2-e DE-627 ger DE-627 rakwb eng Peris, Ketty verfasserin aut Update on the Management of Pediatric Psoriasis: An Italian Consensus 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022. corrected publication 2022 Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis. Adolescents (dpeaa)DE-He213 Biologics (dpeaa)DE-He213 Children (dpeaa)DE-He213 Corticosteroid-sparing (dpeaa)DE-He213 Health-related quality of life (dpeaa)DE-He213 Pediatric psoriasis (dpeaa)DE-He213 Plaque psoriasis (dpeaa)DE-He213 Systemic therapy (dpeaa)DE-He213 Topical corticosteroids (dpeaa)DE-He213 Fortina, Anna Belloni aut Bianchi, Luca aut Fabbrocini, Gabriella aut Gisondi, Paolo aut Balato, Anna aut Bardazzi, Federico aut Bernardini, Nicoletta aut Bonamonte, Domenico aut Bongiorno, Maria Rita aut Buligan, Cinzia aut Cusano, Francesco aut Del Giudice, Maria Beatrice De Felici aut El Hachem, May aut Fargnoli, Maria Concetta aut Gualdi, Giulio aut Guarneri, Claudio aut Hansel, Katharina aut Malara, Giovanna aut Mazzatenta, Carlo aut Micali, Giuseppe aut Narcisi, Alessandra aut Neri, Iria aut Oranges, Teresa aut Panzone, Michele aut Parodi, Aurora aut Restano, Lucia aut Simonetti, Oriana aut Venturini, Marina aut Di Lernia, Vito (orcid)0000-0002-8961-7108 aut Enthalten in Dermatology and therapy Heidelberg : Springer, 2011 12(2022), 8 vom: 01. Juli, Seite 1753-1775 (DE-627)723900000 (DE-600)2680284-3 2190-9172 nnns volume:12 year:2022 number:8 day:01 month:07 pages:1753-1775 https://dx.doi.org/10.1007/s13555-022-00758-2 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 8 01 07 1753-1775
allfields_unstemmed	10.1007/s13555-022-00758-2 doi (DE-627)SPR047789522 (SPR)s13555-022-00758-2-e DE-627 ger DE-627 rakwb eng Peris, Ketty verfasserin aut Update on the Management of Pediatric Psoriasis: An Italian Consensus 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022. corrected publication 2022 Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis. Adolescents (dpeaa)DE-He213 Biologics (dpeaa)DE-He213 Children (dpeaa)DE-He213 Corticosteroid-sparing (dpeaa)DE-He213 Health-related quality of life (dpeaa)DE-He213 Pediatric psoriasis (dpeaa)DE-He213 Plaque psoriasis (dpeaa)DE-He213 Systemic therapy (dpeaa)DE-He213 Topical corticosteroids (dpeaa)DE-He213 Fortina, Anna Belloni aut Bianchi, Luca aut Fabbrocini, Gabriella aut Gisondi, Paolo aut Balato, Anna aut Bardazzi, Federico aut Bernardini, Nicoletta aut Bonamonte, Domenico aut Bongiorno, Maria Rita aut Buligan, Cinzia aut Cusano, Francesco aut Del Giudice, Maria Beatrice De Felici aut El Hachem, May aut Fargnoli, Maria Concetta aut Gualdi, Giulio aut Guarneri, Claudio aut Hansel, Katharina aut Malara, Giovanna aut Mazzatenta, Carlo aut Micali, Giuseppe aut Narcisi, Alessandra aut Neri, Iria aut Oranges, Teresa aut Panzone, Michele aut Parodi, Aurora aut Restano, Lucia aut Simonetti, Oriana aut Venturini, Marina aut Di Lernia, Vito (orcid)0000-0002-8961-7108 aut Enthalten in Dermatology and therapy Heidelberg : Springer, 2011 12(2022), 8 vom: 01. Juli, Seite 1753-1775 (DE-627)723900000 (DE-600)2680284-3 2190-9172 nnns volume:12 year:2022 number:8 day:01 month:07 pages:1753-1775 https://dx.doi.org/10.1007/s13555-022-00758-2 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 8 01 07 1753-1775
allfieldsGer	10.1007/s13555-022-00758-2 doi (DE-627)SPR047789522 (SPR)s13555-022-00758-2-e DE-627 ger DE-627 rakwb eng Peris, Ketty verfasserin aut Update on the Management of Pediatric Psoriasis: An Italian Consensus 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022. corrected publication 2022 Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis. Adolescents (dpeaa)DE-He213 Biologics (dpeaa)DE-He213 Children (dpeaa)DE-He213 Corticosteroid-sparing (dpeaa)DE-He213 Health-related quality of life (dpeaa)DE-He213 Pediatric psoriasis (dpeaa)DE-He213 Plaque psoriasis (dpeaa)DE-He213 Systemic therapy (dpeaa)DE-He213 Topical corticosteroids (dpeaa)DE-He213 Fortina, Anna Belloni aut Bianchi, Luca aut Fabbrocini, Gabriella aut Gisondi, Paolo aut Balato, Anna aut Bardazzi, Federico aut Bernardini, Nicoletta aut Bonamonte, Domenico aut Bongiorno, Maria Rita aut Buligan, Cinzia aut Cusano, Francesco aut Del Giudice, Maria Beatrice De Felici aut El Hachem, May aut Fargnoli, Maria Concetta aut Gualdi, Giulio aut Guarneri, Claudio aut Hansel, Katharina aut Malara, Giovanna aut Mazzatenta, Carlo aut Micali, Giuseppe aut Narcisi, Alessandra aut Neri, Iria aut Oranges, Teresa aut Panzone, Michele aut Parodi, Aurora aut Restano, Lucia aut Simonetti, Oriana aut Venturini, Marina aut Di Lernia, Vito (orcid)0000-0002-8961-7108 aut Enthalten in Dermatology and therapy Heidelberg : Springer, 2011 12(2022), 8 vom: 01. Juli, Seite 1753-1775 (DE-627)723900000 (DE-600)2680284-3 2190-9172 nnns volume:12 year:2022 number:8 day:01 month:07 pages:1753-1775 https://dx.doi.org/10.1007/s13555-022-00758-2 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 8 01 07 1753-1775
allfieldsSound	10.1007/s13555-022-00758-2 doi (DE-627)SPR047789522 (SPR)s13555-022-00758-2-e DE-627 ger DE-627 rakwb eng Peris, Ketty verfasserin aut Update on the Management of Pediatric Psoriasis: An Italian Consensus 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022. corrected publication 2022 Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis. Adolescents (dpeaa)DE-He213 Biologics (dpeaa)DE-He213 Children (dpeaa)DE-He213 Corticosteroid-sparing (dpeaa)DE-He213 Health-related quality of life (dpeaa)DE-He213 Pediatric psoriasis (dpeaa)DE-He213 Plaque psoriasis (dpeaa)DE-He213 Systemic therapy (dpeaa)DE-He213 Topical corticosteroids (dpeaa)DE-He213 Fortina, Anna Belloni aut Bianchi, Luca aut Fabbrocini, Gabriella aut Gisondi, Paolo aut Balato, Anna aut Bardazzi, Federico aut Bernardini, Nicoletta aut Bonamonte, Domenico aut Bongiorno, Maria Rita aut Buligan, Cinzia aut Cusano, Francesco aut Del Giudice, Maria Beatrice De Felici aut El Hachem, May aut Fargnoli, Maria Concetta aut Gualdi, Giulio aut Guarneri, Claudio aut Hansel, Katharina aut Malara, Giovanna aut Mazzatenta, Carlo aut Micali, Giuseppe aut Narcisi, Alessandra aut Neri, Iria aut Oranges, Teresa aut Panzone, Michele aut Parodi, Aurora aut Restano, Lucia aut Simonetti, Oriana aut Venturini, Marina aut Di Lernia, Vito (orcid)0000-0002-8961-7108 aut Enthalten in Dermatology and therapy Heidelberg : Springer, 2011 12(2022), 8 vom: 01. Juli, Seite 1753-1775 (DE-627)723900000 (DE-600)2680284-3 2190-9172 nnns volume:12 year:2022 number:8 day:01 month:07 pages:1753-1775 https://dx.doi.org/10.1007/s13555-022-00758-2 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 8 01 07 1753-1775
language	English
source	Enthalten in Dermatology and therapy 12(2022), 8 vom: 01. Juli, Seite 1753-1775 volume:12 year:2022 number:8 day:01 month:07 pages:1753-1775
sourceStr	Enthalten in Dermatology and therapy 12(2022), 8 vom: 01. Juli, Seite 1753-1775 volume:12 year:2022 number:8 day:01 month:07 pages:1753-1775
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Adolescents Biologics Children Corticosteroid-sparing Health-related quality of life Pediatric psoriasis Plaque psoriasis Systemic therapy Topical corticosteroids
isfreeaccess_bool	true
container_title	Dermatology and therapy
authorswithroles_txt_mv	Peris, Ketty @@aut@@ Fortina, Anna Belloni @@aut@@ Bianchi, Luca @@aut@@ Fabbrocini, Gabriella @@aut@@ Gisondi, Paolo @@aut@@ Balato, Anna @@aut@@ Bardazzi, Federico @@aut@@ Bernardini, Nicoletta @@aut@@ Bonamonte, Domenico @@aut@@ Bongiorno, Maria Rita @@aut@@ Buligan, Cinzia @@aut@@ Cusano, Francesco @@aut@@ Del Giudice, Maria Beatrice De Felici @@aut@@ El Hachem, May @@aut@@ Fargnoli, Maria Concetta @@aut@@ Gualdi, Giulio @@aut@@ Guarneri, Claudio @@aut@@ Hansel, Katharina @@aut@@ Malara, Giovanna @@aut@@ Mazzatenta, Carlo @@aut@@ Micali, Giuseppe @@aut@@ Narcisi, Alessandra @@aut@@ Neri, Iria @@aut@@ Oranges, Teresa @@aut@@ Panzone, Michele @@aut@@ Parodi, Aurora @@aut@@ Restano, Lucia @@aut@@ Simonetti, Oriana @@aut@@ Venturini, Marina @@aut@@ Di Lernia, Vito @@aut@@
publishDateDaySort_date	2022-07-01T00:00:00Z
hierarchy_top_id	723900000
id	SPR047789522
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR047789522</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519155740.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13555-022-00758-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR047789522</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13555-022-00758-2-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Peris, Ketty</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Update on the Management of Pediatric Psoriasis: An Italian Consensus</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2022. corrected publication 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adolescents</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biologics</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Children</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Corticosteroid-sparing</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Health-related quality of life</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pediatric psoriasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Plaque psoriasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systemic therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Topical corticosteroids</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fortina, Anna Belloni</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bianchi, Luca</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fabbrocini, Gabriella</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gisondi, Paolo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balato, Anna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bardazzi, Federico</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bernardini, Nicoletta</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bonamonte, Domenico</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bongiorno, Maria Rita</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buligan, Cinzia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cusano, Francesco</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Del Giudice, Maria Beatrice De Felici</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">El Hachem, May</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fargnoli, Maria Concetta</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gualdi, Giulio</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guarneri, Claudio</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hansel, Katharina</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Malara, Giovanna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mazzatenta, Carlo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Micali, Giuseppe</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Narcisi, Alessandra</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Neri, Iria</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oranges, Teresa</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Panzone, Michele</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parodi, Aurora</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Restano, Lucia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Simonetti, Oriana</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Venturini, Marina</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Di Lernia, Vito</subfield><subfield code="0">(orcid)0000-0002-8961-7108</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Dermatology and therapy</subfield><subfield code="d">Heidelberg : Springer, 2011</subfield><subfield code="g">12(2022), 8 vom: 01. Juli, Seite 1753-1775</subfield><subfield code="w">(DE-627)723900000</subfield><subfield code="w">(DE-600)2680284-3</subfield><subfield code="x">2190-9172</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:8</subfield><subfield code="g">day:01</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:1753-1775</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13555-022-00758-2</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2022</subfield><subfield code="e">8</subfield><subfield code="b">01</subfield><subfield code="c">07</subfield><subfield code="h">1753-1775</subfield></datafield></record></collection>
author	Peris, Ketty
spellingShingle	Peris, Ketty misc Adolescents misc Biologics misc Children misc Corticosteroid-sparing misc Health-related quality of life misc Pediatric psoriasis misc Plaque psoriasis misc Systemic therapy misc Topical corticosteroids Update on the Management of Pediatric Psoriasis: An Italian Consensus
authorStr	Peris, Ketty
ppnlink_with_tag_str_mv	@@773@@(DE-627)723900000
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2190-9172
topic_title	Update on the Management of Pediatric Psoriasis: An Italian Consensus Adolescents (dpeaa)DE-He213 Biologics (dpeaa)DE-He213 Children (dpeaa)DE-He213 Corticosteroid-sparing (dpeaa)DE-He213 Health-related quality of life (dpeaa)DE-He213 Pediatric psoriasis (dpeaa)DE-He213 Plaque psoriasis (dpeaa)DE-He213 Systemic therapy (dpeaa)DE-He213 Topical corticosteroids (dpeaa)DE-He213
topic	misc Adolescents misc Biologics misc Children misc Corticosteroid-sparing misc Health-related quality of life misc Pediatric psoriasis misc Plaque psoriasis misc Systemic therapy misc Topical corticosteroids
topic_unstemmed	misc Adolescents misc Biologics misc Children misc Corticosteroid-sparing misc Health-related quality of life misc Pediatric psoriasis misc Plaque psoriasis misc Systemic therapy misc Topical corticosteroids
topic_browse	misc Adolescents misc Biologics misc Children misc Corticosteroid-sparing misc Health-related quality of life misc Pediatric psoriasis misc Plaque psoriasis misc Systemic therapy misc Topical corticosteroids
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Dermatology and therapy
hierarchy_parent_id	723900000
hierarchy_top_title	Dermatology and therapy
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)723900000 (DE-600)2680284-3
title	Update on the Management of Pediatric Psoriasis: An Italian Consensus
ctrlnum	(DE-627)SPR047789522 (SPR)s13555-022-00758-2-e
title_full	Update on the Management of Pediatric Psoriasis: An Italian Consensus
author_sort	Peris, Ketty
journal	Dermatology and therapy
journalStr	Dermatology and therapy
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
container_start_page	1753
author_browse	Peris, Ketty Fortina, Anna Belloni Bianchi, Luca Fabbrocini, Gabriella Gisondi, Paolo Balato, Anna Bardazzi, Federico Bernardini, Nicoletta Bonamonte, Domenico Bongiorno, Maria Rita Buligan, Cinzia Cusano, Francesco Del Giudice, Maria Beatrice De Felici El Hachem, May Fargnoli, Maria Concetta Gualdi, Giulio Guarneri, Claudio Hansel, Katharina Malara, Giovanna Mazzatenta, Carlo Micali, Giuseppe Narcisi, Alessandra Neri, Iria Oranges, Teresa Panzone, Michele Parodi, Aurora Restano, Lucia Simonetti, Oriana Venturini, Marina Di Lernia, Vito
container_volume	12
format_se	Elektronische Aufsätze
author-letter	Peris, Ketty
doi_str_mv	10.1007/s13555-022-00758-2
normlink	(ORCID)0000-0002-8961-7108
normlink_prefix_str_mv	(orcid)0000-0002-8961-7108
title_sort	update on the management of pediatric psoriasis: an italian consensus
title_auth	Update on the Management of Pediatric Psoriasis: An Italian Consensus
abstract	Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis. © The Author(s) 2022. corrected publication 2022
abstractGer	Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis. © The Author(s) 2022. corrected publication 2022
abstract_unstemmed	Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis. © The Author(s) 2022. corrected publication 2022
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	8
title_short	Update on the Management of Pediatric Psoriasis: An Italian Consensus
url	https://dx.doi.org/10.1007/s13555-022-00758-2
remote_bool	true
author2	Fortina, Anna Belloni Bianchi, Luca Fabbrocini, Gabriella Gisondi, Paolo Balato, Anna Bardazzi, Federico Bernardini, Nicoletta Bonamonte, Domenico Bongiorno, Maria Rita Buligan, Cinzia Cusano, Francesco Del Giudice, Maria Beatrice De Felici El Hachem, May Fargnoli, Maria Concetta Gualdi, Giulio Guarneri, Claudio Hansel, Katharina Malara, Giovanna Mazzatenta, Carlo Micali, Giuseppe Narcisi, Alessandra Neri, Iria Oranges, Teresa Panzone, Michele Parodi, Aurora Restano, Lucia Simonetti, Oriana Venturini, Marina Di Lernia, Vito
author2Str	Fortina, Anna Belloni Bianchi, Luca Fabbrocini, Gabriella Gisondi, Paolo Balato, Anna Bardazzi, Federico Bernardini, Nicoletta Bonamonte, Domenico Bongiorno, Maria Rita Buligan, Cinzia Cusano, Francesco Del Giudice, Maria Beatrice De Felici El Hachem, May Fargnoli, Maria Concetta Gualdi, Giulio Guarneri, Claudio Hansel, Katharina Malara, Giovanna Mazzatenta, Carlo Micali, Giuseppe Narcisi, Alessandra Neri, Iria Oranges, Teresa Panzone, Michele Parodi, Aurora Restano, Lucia Simonetti, Oriana Venturini, Marina Di Lernia, Vito
ppnlink	723900000
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1007/s13555-022-00758-2
up_date	2024-07-03T14:59:23.242Z
_version_	1803570394687340544
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR047789522</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519155740.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13555-022-00758-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR047789522</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13555-022-00758-2-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Peris, Ketty</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Update on the Management of Pediatric Psoriasis: An Italian Consensus</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2022. corrected publication 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adolescents</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biologics</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Children</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Corticosteroid-sparing</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Health-related quality of life</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pediatric psoriasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Plaque psoriasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systemic therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Topical corticosteroids</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fortina, Anna Belloni</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bianchi, Luca</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fabbrocini, Gabriella</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gisondi, Paolo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balato, Anna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bardazzi, Federico</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bernardini, Nicoletta</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bonamonte, Domenico</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bongiorno, Maria Rita</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buligan, Cinzia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cusano, Francesco</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Del Giudice, Maria Beatrice De Felici</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">El Hachem, May</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fargnoli, Maria Concetta</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gualdi, Giulio</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guarneri, Claudio</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hansel, Katharina</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Malara, Giovanna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mazzatenta, Carlo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Micali, Giuseppe</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Narcisi, Alessandra</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Neri, Iria</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oranges, Teresa</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Panzone, Michele</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parodi, Aurora</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Restano, Lucia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Simonetti, Oriana</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Venturini, Marina</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Di Lernia, Vito</subfield><subfield code="0">(orcid)0000-0002-8961-7108</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Dermatology and therapy</subfield><subfield code="d">Heidelberg : Springer, 2011</subfield><subfield code="g">12(2022), 8 vom: 01. Juli, Seite 1753-1775</subfield><subfield code="w">(DE-627)723900000</subfield><subfield code="w">(DE-600)2680284-3</subfield><subfield code="x">2190-9172</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:8</subfield><subfield code="g">day:01</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:1753-1775</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13555-022-00758-2</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2022</subfield><subfield code="e">8</subfield><subfield code="b">01</subfield><subfield code="c">07</subfield><subfield code="h">1753-1775</subfield></datafield></record></collection>
score	7.4008503

Nicht das Richtige dabei?

Schreiben Sie uns!

Update on the Management of Pediatric Psoriasis: An Italian Consensus

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?